Webinar Description:
Join us for a timely and informative webinar unpacking the impact of former President Trump's proposed tariffs on the life sciences sector and the broader healthcare system. As the political landscape shifts and trade policies come back into focus, stakeholders across pharma, medical devices, and digital health need to understand what’s at stake.
In this 30-minute session (including 10 minutes of Q and A), experts will break down:
The basics of tariffs and how they apply to life sciences
Which countries and sectors are impacted by the Trump Administration’s America First Trade Policy
How increased costs may ripple through supply chains, reimbursement, and patient access
What companies can do now to mitigate risk and protect their bottom line
Whether you're in strategy, regulatory affairs, finance, or policy, this webinar will equip you with essential insights to navigate the potential economic and operational impact of these evolving trade dynamics.
Who should attend: Executives, policymakers, trade and regulatory professionals, healthcare investors, and anyone with a stake in the global healthcare market.
https://www.bipc.com/
Our Speakers:
International Trade Advisor
Email: milton.koch@bipc.com
Milton provides analysis to domestic producers in trade remedy litigation, with a particular emphasis on antidumping investigations before the U.S. Department of Commerce. As a Certified Public Accountant and a former analyst at the U.S. Department of Commerce, Milton Koch supports trade litigation clients by developing legal strategies based on in-depth analysis of complex financial data. He has taken a primary role in numerous trade cases providing creative and novel legal solutions to address issues ranging from the business structure of multinational companies to unique subsidy schemes of foreign governments. He serves as an analyst in cases across a number of industries, including manufacturing, finance, and investing. He also assists clients in research matters relating to economic sanctions, national security, and litigation.
Shareholder: Life Sciences Industry Group Co-Leader
Email: tina.hu@bipc.com
Tina is Co-Leader of the firm’s Life Sciences Industry Team, and a shareholder in the FDA/Biotechnology group. She focuses her practice on issues related to the approval, regulation, promotion, sale and reimbursement of drugs, medical devices, biologics, dietary supplements, foods and cannabis-related products.
Tina assists clients in their interactions with various federal agencies including the following:
Food and Drug Administration (FDA)
Centers for Medicare & Medicaid Services (CMS)
Drug Enforcement Administration (DEA)
Federal Trade Commission (FTC)
In addition to advising clients on how to obtain approvals for their FDA-regulated products, Tina's experience includes reviewing and revising the labeling of drugs, medical devices, foods and dietary supplements to ensure compliance with the FDA law and regulations. She works with clients to petition the FDA to ensure the safety and effectiveness of drug products on the market, and assists clients in a wide range of compliance and enforcement matters. She also advises clients on user fee issues, federal and state Sunshine Act reporting obligations, state price transparency disclosure rules, and state licensing requirements.
Tina is a thought leader on artificial intelligence and machine learning in the life sciences industry. She has spoken frequently and published several articles on AI/ML in drug discovery and development as well as FDA’s regulation of AI/ML-powered medical devices.
Tina is also a member of the firm's cannabis group, where she assists companies in navigating federal and state law issues related to the promotion and sale of cannabis-related products. Tina has helped companies work to bring FDA- approved cannabinoid drug products to market, as well as helped clients to navigate sale of cannabis and hemp-related products.
Tina chairs the Buchanan B.O.L.D. Affinity group, and is conversant in Mandarin.
In 2019 and 2020, Tina was named to the Washington, D.C. Super Lawyers Rising Stars list. Most recently, in 2024, Tina was named the Rising Star Award winner by the Leadership Council on Legal Diversity.